How To Play This “Post-Election Bounce” Trend
Today’s article highlights a group of companies that tend to decline before an election – underperforming the stock market by over one-third as we move towards an election – and then recover.
Today’s article highlights a group of companies that tend to decline before an election – underperforming the stock market by over one-third as we move towards an election – and then recover.
The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason? Their respective COVID-19 vaccine development programs, which have moved at lightning-fast speed.
One billion dollars. Big things happen when a company reaches this threshold in annual sales.
“The fact that more than 9 months of this year have been focused on the space is unfounded. In fact, I don’t remember one industry in recent history that has so captivated the stock market as much as this,” says the author of today’s article of the biotech space – and biotech penny stocks in particular.
While the surge in interest in pharmaceutical stocks this year has been primarily driven by factors related to the COVID-19 pandemic, the author of today’s article advises that “companies working on pharmaceutical products for unmet needs or other niche markets such as animal health could be worth a closer look.”
“Many scientists believe that this year could be a breakthrough in finding cures for cancer in DNA and investors could get familiar with terms like CRISPR and precision medicine to make the most out of advancements in this space.”
Heading into an earnings season in which many companies will be posting much lower earnings as a result of the pandemic.
Three biotech companies developing therapies for the treatment of cancer and other diseases – including infectious diseases like COVID-19 – began trading on Friday.
A trio of biotech firms IPOed on Friday – and saw double-digit gains on their trading debuts.
A look at the four biotech companies going public Friday – which include two firms developing small molecule therapies to treat cancer.